CN105917007A - Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 - Google Patents

Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 Download PDF

Info

Publication number
CN105917007A
CN105917007A CN201580004684.5A CN201580004684A CN105917007A CN 105917007 A CN105917007 A CN 105917007A CN 201580004684 A CN201580004684 A CN 201580004684A CN 105917007 A CN105917007 A CN 105917007A
Authority
CN
China
Prior art keywords
loh
cancer
genome
parp inhibitor
ricaparib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580004684.5A
Other languages
English (en)
Chinese (zh)
Inventor
K·林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clovis Oncology Inc
Original Assignee
Clovis Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clovis Oncology Inc filed Critical Clovis Oncology Inc
Publication of CN105917007A publication Critical patent/CN105917007A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580004684.5A 2014-01-16 2015-01-14 Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 Pending CN105917007A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461928326P 2014-01-16 2014-01-16
US61/928,326 2014-01-16
US201462004424P 2014-05-29 2014-05-29
US62/004,424 2014-05-29
US201462039516P 2014-08-20 2014-08-20
US62/039,516 2014-08-20
US201462076165P 2014-11-06 2014-11-06
US62/076,165 2014-11-06
PCT/US2015/011413 WO2015108986A1 (en) 2014-01-16 2015-01-14 Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity

Publications (1)

Publication Number Publication Date
CN105917007A true CN105917007A (zh) 2016-08-31

Family

ID=53543398

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580004684.5A Pending CN105917007A (zh) 2014-01-16 2015-01-14 Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途

Country Status (5)

Country Link
US (1) US20180163271A1 (enExample)
EP (1) EP3094752A4 (enExample)
JP (1) JP6663350B2 (enExample)
CN (1) CN105917007A (enExample)
WO (1) WO2015108986A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110062628A (zh) * 2016-12-16 2019-07-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
CN118995870A (zh) * 2024-06-27 2024-11-22 华中科技大学同济医学院附属同济医院 PARP抑制剂Veliparib在筛除BRCA1杂合突变胚胎中的应用和方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512485B2 (en) 2010-08-24 2016-12-06 Dana-Farber Cancer Institute. Inc. Methods for predicting anti-cancer response
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
DK2794907T4 (da) 2011-12-21 2023-02-27 Myriad Genetics Inc Fremgangsmåder og materialer til vurdering af tab af heterozygositet
EP2817630B1 (en) 2012-02-23 2018-07-11 Children's Medical Center Corporation Methods for predicting anti-cancer response
CA3190075A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
ES2775579T3 (es) 2013-10-04 2020-07-27 Aptose Biosciences Inc Composiciones para el tratamiento del cáncer
EP4023765A1 (en) 2013-12-09 2022-07-06 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
ES2800673T3 (es) 2014-08-15 2021-01-04 Myriad Genetics Inc Métodos y materiales para evaluar una deficiencia de recombinación homóloga
EP3230472A4 (en) * 2014-12-08 2018-06-13 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
JP6763114B2 (ja) * 2016-06-02 2020-09-30 国立大学法人 琉球大学 オオフトモモ抽出物を含むｐａｒｐ阻害剤
MX394062B (es) * 2016-06-29 2025-03-19 Tesaro Inc Métodos para el tratamiento del cáncer ovárico.
KR20200018436A (ko) 2017-05-09 2020-02-19 테사로, 인코포레이티드 암 치료를 위한 조합 요법
CA3063715A1 (en) 2017-05-18 2018-11-22 Tesaro, Inc. Combination therapies for treating cancer
FI3688155T3 (fi) 2017-09-28 2023-03-30 Immpact Bio Ltd Universaali alusta inhibitorisen kimeerisen antigeenireseptorin (icar) valmistamiseksi
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
CA3076859A1 (en) 2017-10-06 2019-04-11 Tesaro, Inc. Combination therapies and uses thereof
AU2018360477A1 (en) * 2017-10-30 2020-06-04 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
EP3703669B1 (en) * 2017-11-01 2025-08-06 Dana-Farber Cancer Institute, Inc. Usp1 or uaf1 inhibitors for use in treating cancer
US20210047693A1 (en) * 2017-11-15 2021-02-18 The Regents Of The University Of California Methods of treating extrachromosomal dna expressing cancers
CR20200334A (es) 2018-01-05 2021-03-09 Cybrexa 1 Inc Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
WO2019195443A1 (en) * 2018-04-04 2019-10-10 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor
WO2020163170A1 (en) * 2019-02-05 2020-08-13 The Board Of Regents Of The University Of Texas System Trapping-free parp inhibitors
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
PH12022550039A1 (en) 2019-07-10 2023-06-26 Cybrexa 3 Inc Peptide conjugates of cytotoxins as therapeutics
PL4143182T3 (pl) 2020-04-28 2025-03-31 Rhizen Pharmaceuticals Ag Nowe związki użyteczne jako inhibitory polimerazy poli(adprybozy) (parp)
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase
WO2025078404A1 (en) * 2023-10-10 2025-04-17 Vib Vzw Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120015050A1 (en) * 2010-06-18 2012-01-19 Myriad Genetics, Incorporated Methods and materials for assessing loss of heterozygosity
US20130281312A1 (en) * 2010-08-24 2013-10-24 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027650A1 (en) * 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
US8729048B2 (en) * 2011-11-22 2014-05-20 Mayo Foundation For Medical Education And Research Methods and materials for assessing responsiveness to PARP inhibitors and platinating agents
AU2012342562B2 (en) * 2011-11-25 2017-02-23 Nerviano Medical Sciences S.R.L. 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors
WO2013133876A1 (en) * 2011-12-07 2013-09-12 The Regents Of The University Of California Biomarkers for prediction of response to parp inhibition in breast cancer
DK2794907T4 (da) * 2011-12-21 2023-02-27 Myriad Genetics Inc Fremgangsmåder og materialer til vurdering af tab af heterozygositet
EP2817630B1 (en) * 2012-02-23 2018-07-11 Children's Medical Center Corporation Methods for predicting anti-cancer response
CA3190075A1 (en) * 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120015050A1 (en) * 2010-06-18 2012-01-19 Myriad Genetics, Incorporated Methods and materials for assessing loss of heterozygosity
US20130281312A1 (en) * 2010-08-24 2013-10-24 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FONG ET AL.: "Inhibiton of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers", 《N ENGL J MED》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110062628A (zh) * 2016-12-16 2019-07-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
CN110062628B (zh) * 2016-12-16 2023-02-17 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
CN118995870A (zh) * 2024-06-27 2024-11-22 华中科技大学同济医学院附属同济医院 PARP抑制剂Veliparib在筛除BRCA1杂合突变胚胎中的应用和方法

Also Published As

Publication number Publication date
EP3094752A1 (en) 2016-11-23
JP2017504623A (ja) 2017-02-09
JP6663350B2 (ja) 2020-03-11
EP3094752A4 (en) 2017-08-16
WO2015108986A1 (en) 2015-07-23
US20180163271A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
CN105917007A (zh) Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途
US20250250643A1 (en) Methods and materials for assessing loss of heterozygosity
JP6700333B2 (ja) ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
Huss et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p. D419del)
Philpott et al. The NF1 somatic mutational landscape in sporadic human cancers
ES2909899T3 (es) Métodos para detectar inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
Belinsky et al. Overexpression of insulin‐like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild‐type SDHB‐negative gastrointestinal stromal tumors
Castro et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer
WO2019201186A1 (zh) 鉴别及评价肿瘤进展的装置和方法
Ma et al. First evidence for the contribution of the genetic variations of BRCA1-interacting protein 1 (BRIP1) to the genetic susceptibility of cervical cancer
Nastase et al. Integrated genomics point to immune vulnerabilities in pleural mesothelioma
Zhang et al. Molecular heterogeneity of head and neck squamous cell carcinoma defined by next-generation sequencing
Yang et al. Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions
Kim et al. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
Xu et al. XRCC2 rs3218536 polymorphism decreases the sensitivity of colorectal cancer cells to poly (ADP‑ribose) polymerase 1 inhibitor
Lourenço et al. Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors
US9512486B2 (en) Materials, methods, and systems for treating cancer
Shah et al. Association of PKCi variant and its gene expression with breast cancer prognosis
Kwan An investigation into the non-coding genomic landscape and effects of chemotherapeutics in pre-treated advanced cancers
TW202505037A (zh) 用於評估乳癌亞型中同源重組缺陷之方法及材料
Tirtei Tumour Genomic Profile Analysis in Children, Adolescents and Young Adults With Bone Sarcomas: a national multi-centre prospective trial
Van der Merwe Development and application of a pathology supported pharmacogenetic test for improved clinical management of South African patients with breast cancer and associated comorbidities
Webb et al. EGFR mutation testing in NSCLC: patterns of care and outcomes in Western Australia
Haller The emerging role of mutational analysis in the management of gastrointestinal stromal tumour
Ahmed Hereditary Breast Cancer in Selected Populations: Screening RECQL Gene in Ontario, Canada, and Exploring BRCA1/2 and PALB2 in the Caribbean

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160831

WD01 Invention patent application deemed withdrawn after publication